Hamburg, Germany – October 23, 2024 – BioAgilytix, a leading global bioanalytical laboratory, is proud to announce the appointment of Dr. Kay Schroeter as the new General Manager of its recently expanded Hamburg, Germany site. Dr. Schroeter will lead BioAgilytix’s ongoing European expansion, further enhancing its extensive bioanalytical services. Under his leadership, the Hamburg lab will broaden its advanced qPCR offerings, including biodistribution, persistence, vector shedding, gene expression, and biomarker support, while also strengthening its GMP services and CMC testing capabilities.

Dr. Schroeter brings over 21 years of experience in the global clinical trials industry and has held significant leadership roles, most recently as the Global Senior Director Scientific Affairs at Q2 Solutions. His expertise in operational efficiency, fostering cross-functional collaboration, and building strong client partnerships positions him as the ideal leader to drive the European Headquarters’ expansion. Under Dr. Schroeter’s leadership, the Hamburg site will focus on enhancing service delivery, streamlining project workflows, and strengthening relationships with European pharmaceutical and biotech clients, ensuring continued excellence and growth in the region.

“We are pleased to welcome Dr. Kay Schroeter to the BioAgilytix team,” said Davide Molho, CEO of BioAgilytix. “His deep industry knowledge, commitment to innovation, and strong leadership skills align perfectly with our company’s values. We are confident that under his guidance, our Hamburg lab will continue to thrive and deliver exceptional assay development, validation, and testing services globally.”

Under Dr. Schroeter’s leadership, BioAgilytix is poised to enhance its mission of delivering world-class bioanalytical services globally. The company is undergoing a global expansion, which includes new and enhanced facilities in Durham, NC, San Diego, CA, Hamburg, Germany, and facilities in Brisbane and Melbourne, Australia, enhancing BioAgilytix’s support for every phase of drug development.  

About BioAgilytix

BioAgilytix is the trusted partner for bioanalytical services throughout every phase of the drug development process. As a leading global bioanalytical laboratory, the company provides established and emerging pharmaceutical and biotechnology organizations with pharmacokinetic (PK), immunogenicity, biomarker, and CMC bioanalytical testing services in a GxP environment. BioAgilytix maintains state-of-the-art laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia; and Hamburg, Germany. For more information, please visit www.bioagilytix.com.  

For more information, please contact:

Noelle Brawner
Communications Manager
BioAgilytix Labs, LLC
Noelle.brawner@bioagilytix.com